Tissue plasminogen activator (tPA) is made using recombinant DNA technology, where the human gene for tPA is inserted into living cells that are then grown in large-scale bioreactors to produce the protein. The finished product, sold under the brand name Activase (alteplase), is a purified glycoprotein made up of 527 amino acids with a biological potency of 580,000 International Units per milligram. The process from gene to injectable drug involves genetic engineering, cell culture, purification, viral safety steps, and final formulation into a freeze-dried powder.
The Gene Behind the Drug
The starting point is the human gene that codes for tPA. In nature, your body produces small amounts of tPA to dissolve blood clots. To make it as a drug, scientists isolate the DNA sequence for tPA (or a functional portion of it) and insert it into a specially designed carrier called a vector. The vector acts like a delivery vehicle, carrying the tPA gene into a host cell where it can be read and used to build the protein.
Researchers use restriction enzymes to cut both the tPA gene and the vector at precise locations, then join them together. The resulting recombinant vector is introduced into host cells through a process called transformation. Once inside the cell, the tPA gene integrates into the cell’s machinery, and the cell begins producing tPA as though it were one of its own proteins. A chemical called methotrexate is often used during cell line development to amplify the number of gene copies inside each cell, boosting protein output.
Why Chinese Hamster Ovary Cells
The host cells of choice for commercial tPA production are Chinese Hamster Ovary (CHO) cells. These cells dominate biopharmaceutical manufacturing because they can produce complex proteins with the correct post-translational modifications, meaning the chemical decorations (particularly sugar chains) that the protein needs to function properly in the human body. Bacteria like E. coli can also produce fragments of tPA and have been used in research settings, but they lack the cellular machinery to attach these sugar chains or fold the full protein correctly.
tPA is a structurally demanding protein. It contains 17 disulfide bonds, which are chemical bridges that hold the protein in its correct three-dimensional shape. Research has shown that if these bonds don’t form properly during production, the protein’s sugar chain pattern changes and the molecule doesn’t fold or get secreted from cells normally. CHO cells handle this complexity well because their internal protein-folding environment closely mimics that of human cells. They’re also robust, adapt easily to suspension culture in large bioreactors, and resist viral infection, all practical advantages at manufacturing scale.
Growing Cells in Bioreactors
Once a stable CHO cell line is established, it’s scaled up from small culture dishes to industrial bioreactors. During the growth phase, cells are maintained at 37°C in a controlled atmosphere containing 5% carbon dioxide, which helps regulate the pH of the culture medium. The CO₂ dissolves into the liquid and acts as a buffering system, keeping conditions stable for the cells.
The culture medium provides everything the cells need to survive and produce tPA. A typical formulation starts with a base nutrient mix (such as Ham’s F-12), supplemented with sodium bicarbonate for additional pH buffering, glucose and glutamine as the primary energy and carbon sources, and antibiotics to prevent contamination. Some formulations include serum, a blood-derived supplement rich in growth factors, though modern processes increasingly use serum-free media to reduce variability and simplify downstream purification. Throughout cultivation, glucose and glutamine levels are monitored because these nutrients are consumed rapidly by growing cells and directly influence both cell health and tPA yield.
The CHO cells secrete tPA into the surrounding liquid (the culture supernatant), which means the protein accumulates outside the cells. This is a significant manufacturing advantage because it simplifies collection: the cells can be separated from the liquid, and the tPA-rich supernatant moves on to purification.
Purifying the Protein
The culture supernatant is a crude mixture containing tPA along with thousands of other proteins, cell debris, and metabolic byproducts. Purification strips away everything that isn’t tPA through a series of chromatography steps, each exploiting a different physical property of the protein.
A key technique is hydrophobic interaction chromatography, where tPA binds to a column material based on its water-repelling surface regions. The column is washed to remove impurities, then tPA is released using a solution of 15 to 30 percent isopropyl alcohol. This step can capture tPA directly from the crude supernatant, which is an advantage over older processes that required an initial affinity chromatography step. After this capture, an optional ion exchange chromatography step separates remaining contaminants based on their electrical charge, further polishing the product.
This multi-step approach yields a highly pure protein. The final product must meet strict biological potency standards verified by an in vitro clot-dissolving assay before it can be released for clinical use.
Ensuring Viral Safety
Because tPA is produced in animal-derived cells, the manufacturing process includes multiple dedicated steps to eliminate any potential viral contamination. These form a layered defense so that no single step bears the full burden of safety.
Enveloped viruses (those with a fatty outer coating) are inactivated through low-pH incubation or detergent treatment, which disrupts their outer membranes. Virus filtration provides a physical barrier, passing the product through filters with pores small enough to block viral particles while allowing tPA molecules through. The chromatography steps used during purification also contribute to viral clearance, with different column types removing different virus categories. Anion exchange membranes, for example, are particularly effective against small non-enveloped viruses. Together, these orthogonal methods, each working by a different mechanism, provide a high cumulative level of viral removal and inactivation.
Final Formulation
After purification and viral safety processing, the tPA solution is formulated with stabilizing agents and then freeze-dried (lyophilized) into a powder. The commercial product, Activase, comes in 50 mg and 100 mg vials. A 100 mg vial contains 58 million International Units of clot-dissolving activity. Before administration, healthcare providers reconstitute the powder with sterile water, creating a solution that’s delivered intravenously.
The lyophilized format is critical for practical reasons. tPA is a fragile protein, and storing it as a dry powder extends its shelf life and makes it easier to stock in hospital pharmacies and emergency departments where rapid access matters.
Next-Generation Versions
The same basic manufacturing platform has been used to produce improved versions of tPA. Tenecteplase, the most notable second-generation variant, is made by modifying the alteplase gene at three positions, changing a total of six amino acids. These substitutions give tenecteplase a longer half-life in the bloodstream, greater selectivity for clots over circulating proteins, and increased resistance to the body’s natural tPA inhibitor (PAI-1). The result is a drug that can be given as a single injection rather than the prolonged infusion required for alteplase, a meaningful practical improvement in emergency settings like stroke treatment.
The production process for tenecteplase follows the same general framework: gene insertion into CHO cells, bioreactor culture, chromatographic purification, viral clearance, and lyophilization. The key difference is the engineered gene itself, which encodes the modified protein from the start.